Laia Agell

Laia Agell

Auto-generated profile, based on publicly available information

Laia Agell

Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in Laboratory Investigation
Verified
Journal Article
Closed access
SHSilvia Hernández-Llodrà
Silvia Hernández-Llodrà
SMSilvia de Muga
Silvia de Muga
LALaia Agell
Laia Agell
NJNuria Juanpere
Nuria Juanpere
RERaquel Esgueva
Raquel Esgueva
JLJosep Lloreta
Josep Lloreta

1 October 2012 in Human Pathology
Verified
Journal Article
Closed access
NJNuria Juanpere
Nuria Juanpere
LALaia Agell
Laia Agell
MLMarta Lorenzo
Marta Lorenzo
SMSilvia de Muga
Silvia de Muga
LLLaura López-Vilaró
Laura López-Vilaró
SHSilvia Hernández
Silvia Hernández

5 March 2010 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
SMSilvia de Muga
Silvia de Muga
SHSilvia Hernández-Llodrà
Silvia Hernández-Llodrà
LALaia Agell
Laia Agell
MSMarta Salido
Marta Salido
NJNuria Juanpere
Nuria Juanpere
JLJosep Lloreta
Josep Lloreta
Prostate cancer is the second cause of cancer-related death in men of the Western world. The potential prognostic role of the combined alterations in EGFR and PTEN in prostate cancer is not well established. It was the aim of the study to investigate this role. Prevalence of EGFR and PTEN somatic mutations, EGFR amplification and EGFR protein expression were investigated in a series of prostate adenocarcinomas, classified according to the current Gleason grading system. Mutational analysis revealed eight EGFR and three PTEN mutations in 98 (8%) and 92 (3%) prostate adenocarcinomas, respectively. The combined prevalence of EGFR–PTEN mutations was 11%. EGFR overexpression was present in 31% of adenocarcinomas, with a marginally significant difference (P=0.068) between Gleason grade ≤7 adenocarcinomas and Gleason grade ≥8 and metastatic adenocarcinomas. Four cases (4 of 31; 13%) had an EGFR gene gain due to chromosome 7 polysomy. In 35% of adenocarcinomas we found some type of EGFR–PTEN alteration, with a tendency to be associated with advanced-stage prostate adenocarcinomas (P=0.04). The IVS18+19 polymorphism was also associated with more advanced prostate adenocarcinomas. This is the first study reporting mutations of EGFR and PTEN in the same series of prostate adenocarcinomas. Protein overexpression is the most frequent EGFR abnormality. Mutations in EGFR and PTEN genes are a minor event, although prostate cancer represents the third neoplasm in which the EGFR gene mutations are more prevalent. Alterations in the EGFR–PTEN signaling pathway are present in a third of prostate adenocarcinomas, particularly affecting the more advanced cases.

1 November 2012 in The American Journal of Pathology
Verified
Journal Article
Closed access
LALaia Agell
Laia Agell
SHSilvia Hernández
Silvia Hernández
LNLara Nonell
Lara Nonell
MLMarta Lorenzo
Marta Lorenzo
EPEulàlia Puigdecanet
Eulàlia Puigdecanet
JLJosep Lloreta
Josep Lloreta

1 December 2008 in Laboratory Investigation
Verified
Journal Article
Closed access
LALaia Agell
Laia Agell
SHSilvia Hernández
Silvia Hernández
SMSilvia de Muga
Silvia de Muga
JLJosé A Lorente
José A Lorente
NJNúria Juanpere
Núria Juanpere
JLJosep Lloreta
Josep Lloreta

1 March 2011 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
LALaia Agell
Laia Agell
SHSilvia Hernández
Silvia Hernández
MSMarta Salido
Marta Salido
SMSilvia de Muga
Silvia de Muga
NJNuria Juanpere
Nuria Juanpere
JLJosep Lloreta
Josep Lloreta